Mizuho Downgrades BioXcel Therapeutics to Neutral, Lowers Price Target to $4
Portfolio Pulse from richadhand@benzinga.com
Mizuho analyst Graig Suvannavejh has downgraded BioXcel Therapeutics from Buy to Neutral and lowered the price target from $40 to $4.

August 15, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioXcel Therapeutics has been downgraded from Buy to Neutral by Mizuho, with a significant reduction in price target from $40 to $4.
The downgrade from Buy to Neutral indicates a less optimistic outlook for the company's stock. The drastic reduction in price target from $40 to $4 suggests that the analyst believes the stock is overvalued at its current price, which could lead to a decrease in the stock's price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100